Human IVIG treatment in a neurological disease model for Enterovirus A71 infection in 28-day-old AG129 mice

Emerovirm A7: can cause tedous aeurolog.cal ul_i_aat :n yoans chil. ren. Animal mo:els sor EV-A71 are neede: to e:aluate potential antiviral therapies. Exisring models have limitations, inclu ding tack or lethality or crucial disease sign. Here we report the development of an i:V A71 model in 28-day-old mice. Virus was serially passaged until it produced consistent lethality and rear-limb paralysis. unset of disease occtuted between days 6-9 post-infection, with monality following weight loss and netuological signs on days 9-14. In addition, a single administration of human intravenotts inunttnoglobulin at doses of 200, 400 and 800 mg/kg at 4h post-infection was evaluated in the model. Protection from weight loss, netuological sign, and monality (between 50 and 89%) were observed at doses of 400 mg/kg or greater. Based on these results, IVIG was selected for use as a positive connbl in this acute model, and suggest that MG is a potential therapeutic for EV-A71 infections.